News & Events

Read about our latest product developments and partnerships, industry advances and events.

Cerecin appoints two new members to its Scientific Advisory Board following announcement of new Singapore headquarters

October 16, 2018

Professor Chua Nam-Hai and Associate Professor Christopher Chen will provide scientific advisory support as Cerecin continues development of brain health and dementia solutions and expands into the Asian market

SINGAPORE, 16 OCTOBER 2018: Brain health-focused pharmaceutical company Cerecin, today announced the appointment of two healthcare industry leaders to its Scientific Advisory Board (SAB). They are Associate Professor Christopher Chen from the Department of Pharmacology at the National University of Singapore's Yong Loo Lin School of Medicine (NUS Medicine), and Professor Chua Nam-Hai, Chief Scientific Advisor, Wilmar International Limited, Deputy Chairman, Temasek Life Sciences Laboratory and Distinguished Visiting Professor, Department of Biochemistry, NUS Medicine, and a Fellow of the UK Royal Society. They join continuing SAB members Dr. Jeff Cummings of the Cleveland Clinic, Dr. Martin Farlow of the University of Indiana, Dr. Michael Weiner of the University of California San Francisco, and Dr. Bruno Vellas of the Université de Toulouse.

These appointments reaffirm Cerecin's commitment to growth in Asia and its confidence in its new home in Singapore. Both Associate Professor Chen and Professor Chua bring with them a great wealth of knowledge in the fields of neuroscience, biology and the Asian life science ecosystem.

Dr. Charles Stacey, President and CEO of Cerecin, commented: "We are excited to welcome Associate Professor Chen and Professor Chua to our Scientific Advisory Board composed of international thought leaders. We are confident that Cerecin will benefit immensely from Professor Chua's profound knowledge in biotechnology and the life science environment in Asia, as well as Associate Professor Chen's expertise in dementia and rich experience in conducting stroke and dementia clinical trials."

"I am honored to become part of Cerecin's Scientific Advisory Board. I am keenly interested in Cerecin's success, given Wilmar's recent investment in this neurology focused pharma company, and my long term commitment to scientific pursuits. I hope to help the two organizations realize the many synergies that present themselves," said Professor Chua.

"I am excited to be joining the Scientific Advisory Board of Cerecin given how important brain health will be for Asia and us here in Singapore. We are expecting the number of people suffering from dementia here in Singapore to more than double by 2030. Cerecin's product development work is of critical importance to us and I look forward to supporting their efforts," said Associate Professor Chen.

Both Professor Chua and Associate Professor Chen join the Scientific Advisory Board at a time when Cerecin looks to renew its commitment to drug development and increase its offering to the Asian market, cementing its leading position in pioneering novel therapeutic approaches to treat neurodegenerative disease globally.